Quality of life in 1000 patients with early relapsing–remitting multiple sclerosis
Abstract
Background and purpose To examine the quality of life (QoL) in a large cohort of untreated patients with relapsing-remitting multiple sclerosis (RRMS) and to investigate the impact of intramuscular (IM) interferon beta-1a (IFNbeta-1a) treatment. Methods Prospective, observational, open-label, multicentre study conducted in Germany. Untreated patients with RRMS who initiated treatment with IM IFNbeta-1a were included and followed for 12 months. QoL was measured using the EQ-5D questionnaire. Clinical response was assessed by relapse rate and disability (Expanded Disability Status Scale; EDSS). Results A total of 1157 patients were included [mean age 37.6 years, median disease duration 13 months, mean relapse rate 1.7 (95%CI: 1.58-1.73), median EDSS score 2.0]. Relapse rate was reduced to 0.6 at 12 months (95%CI: 0.51-0.69, P Conclusions Quality of life is considerably impaired in early stages of MS. Treatment initiation with IM IFNbeta attenuates MS disease activity and improves QoL. Inability to work early during the disease is a major challenge for the social security systems.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HRQOL has gained increasing status as a metric of treatment effectiveness.
“although HRQOL has gained increasing status as a metric of treatment effectiveness.11–14,20”
From MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial (2010) · cites this paper as [11]
Many disease-modifying drug regimens appear to produce modest or no improvements in HRQOL or even negative changes.
“many disease-modifying drug regimens appear to produce modest or no improvements in HRQOL7,11–14 or even negative changes.15”
From MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial (2010) · cites this paper as [11]
Disease-modifying treatments do not necessarily have beneficial impact upon HRQOL or coping responses.
“Disease-modifying treatments do not necessarily have beneficial impact upon HRQOL or coping responses.7,11–13”
From MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial (2010) · cites this paper as [11]
Cites
Variations in population health status: results from a United Kingdom national questionnaire survey
Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998) · BMJ · doi:10.1136/bmj.316.7133.736 · Cited by 1,059 · see citing works
Coping and Quality of Life in One Hundred and Thirty Five Subjects with Multiple Sclerosis
Montel, S. R., & Bungener, C. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506071170 · Cited by 124 · see citing works
Zivadinov, R., Zorzon, M., Tommasi, M. A., Nasuelli, D., Bernardi, M., Monti-Bragadin, L., & Cazzato, G. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00225-9 · Cited by 81 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial
Grossman, P., Kappos, L., Gensicke, H., D'Souza, M., Mohr, D. C., Penner, I. K., & Steiner, C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f4d80d · Cited by 419 · see citing works
- Authors
- Putzki, N., Fischer, J., Gottwald, K., Reifschneider, G., Ries, S., Siever, A., Hoffmann, F., Käfferlein, W., Kausch, U., Liedtke, M., Kirchmeier, J., Gmünd, S., Richter, A., Schicklmaier, P., Niemczyk, G., Wernsdörfer, C., Hartung, H. P., & for the “Mensch im Mittelpunkt” Study Group
- Affiliations
- Kantonsspital St. Gallen (CH)
- University of Duisburg-Essen (DE)
- Corresponding author
- Putzki, N.
- ORCID
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2009-04-28
- Volume
- 16
- Issue
- 6
- Pages
- 713-720
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2017413546
- Cited by
- 80
- References
- 3
- Citations by year
- 2024: 1 · 2023: 1 · 2021: 3 · 2020: 3 · 2019: 4 · 2018: 8 · 2017: 3 · 2016: 7 · 2015: 12 · 2014: 7 · 2013: 6 · 2012: 8
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- relapsing-remitting multiple sclerosis, quality of life, interferon beta-1a, untreated patients, relapse rate, disability progression, EQ-5D, inability to work, disease activity, early-stage disease
- MeSH terms
- Interferon beta-1a, Adaptation, Psychological, Adjuvants, Immunologic, Adult, Disability Evaluation, Female, Germany, Health Status, Humans, Male, Middle Aged, Prospective Studies, Quality of Life, Surveys and Questionnaires, Recurrence, Severity of Illness Index, Time Factors, Cohort Studies, Interferon-beta, Health Care Costs, Outcome Assessment, Health Care, Sick Leave, Multiple Sclerosis, Relapsing-Remitting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
